Guidant Corporation announces market release of ENDOTAK SQ Lead Array.INDIANAPOLIS--(HealthWire)--April 19, 1995--Guidant Corporation (NYSE NYSE See: New York Stock Exchange :GDT) today announced the U.S. market release of the ENDOTAK(R) SQ Lead Array. The Array is used with CPI's ENDOTAK lead to provide monitoring and energy delivery for implanted defibrillation Defibrillation Definition Defibrillation is a process in which an electronic device sends an electric shock to the heart to stop an extremely rapid, irregular heartbeat, and restore the normal heart rhythm. systems in patients with increased defibrillation energy requirements. The ENDOTAK system is used in conjunction with CPI's VENTAK(R) AICD AICD activation-induced cell death; automatic implantable cardioverter-defibrillator. (TM) automatic implantable cardioverter defibrillator pulse generators to provide therapies for controlling life-threatening rapid heart rhythms (tachycardia) as well as treatment of slow heartbeats (bradycardia bradycardia: see arrhythmia. ). During routine VENTAK/ENDOTAK system implants, a physician generally uses the ENDOTAK system in the lead-alone configuration. A few patients, however, have higher energy delivery requirements to convert their life threatening arrhythmia(s) and require or would benefit from an extra energy delivery electrode. Historically, these patients received a patch electrode implanted under the skin. Physicians can now offer the ENDOTAK SQ Lead Array to these patients, with the following significant benefits: o lower energy requirement for treatment of abnormal heart rhythms. o easier and less invasive implantation. The ENDOTAK SQ Array comprises three long ``fingers'' that deliver the electrical energy, as opposed to a solid patch electrode. o reduced patient complications and discomfort. ``ENDOTAK is already recognized as the `gold standard' in defibrillation lead design,'' noted Jay Graf, president of CPI and a Guidant vice president. ``The market release of the SQ Array enhances the full product line of ENDOTAK components for treating patients with life-threatening arrhythmias.'' A leader in the medical device industry, Guidant Corporation provides innovative, cost-effective products and services to the global cardiology and minimally invasive surgery minimally invasive surgery Laparoscopic surgery, see there. See Laparoscopic cholecystectomy. marketplaces. Guidant comprises Advanced Cardiovascular Systems, Inc. (ACS (Asynchronous Communications Server) See network access server. ), Cardiac Pacemakers, Inc. (CPI), Devices for Vascular Intervention, Inc. (DVI), Heart Rhythm Technologies, Inc. (HRT HRT abbr. hormone replacement therapy Hormone replacement therapy (HRT) Also called estrogen replacement therapy, this controversial treatment is used to relieve the discomforts of menopause. ), and Origin Medsystems, Inc., and the Company's international affiliates. CPI manufactures heart pacemaker systems, automatic implantable cardioverter defibrillators, lead systems and related products. CONTACT: Guidant Corporation David W. Pomfret, 317/971-2031 or CPI Carol A. Lindahl, 612/582-4461 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion